Saltar al contenido
Merck
Todas las fotos(1)

Documentos

P2900000

Prednisona

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

1,4-Pregnadieno-17α,21-diol-3,11,20-triona, 1- Cortisona, 17α,21-dihidroxi-1,4-pregnadieno-3,11,20-triona, Dehidrocortisona

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H26O5
Número de CAS:
53-03-2
Peso molecular:
358.43
Beilstein/REAXYS Number:
2065301
MDL number:
MFCD00003608
UNSPSC Code:
41116107
PubChem Substance ID:
329820154
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

prednisone

manufacturer/tradename

EDQM

mp

236-238 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1

InChI

1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

InChI key

XOFYZVNMUHMLCC-ZPOLXVRWSA-N

Gene Information

human ... NR3C1(2908)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Prednisone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H373

pcodes

P260

Hazard Classifications

STOT RE 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Karim Fizazi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(7), 723-731 (2015-01-28)
Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy. In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive
Fred Saad et al.
The Lancet. Oncology, 16(3), 338-348 (2015-02-24)
Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this phase 3, double-blind
Lindsay Sonstein et al.
The American journal of medicine, 127(11), 1097-1104 (2014-06-15)
Clinical practice guidelines recommend 40-60 mg of prednisone equivalent for 10-14 days for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the amount of corticosteroid prescribed varies widely in clinical practice. Using the electronic health record, we
Claudine Angela Blum et al.
Lancet (London, England), 385(9977), 1511-1518 (2015-01-23)
Clinical trials yielded conflicting data about the benefit of adding systemic corticosteroids for treatment of community-acquired pneumonia. We assessed whether short-term corticosteroid treatment reduces time to clinical stability in patients admitted to hospital for community-acquired pneumonia. In this double-blind, multicentre
Katalin A Wilkinson et al.
Journal of immunology (Baltimore, Md. : 1950), 194(4), 1748-1754 (2015-01-16)
Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) frequently complicates combined antiretroviral therapy and antituberculosis therapy in HIV-1-coinfected tuberculosis patients. The immunopathological mechanisms underlying TB-IRIS are incompletely defined, and improved understanding is required to derive new treatments and to reduce associated morbidity
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico